Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ciclesonide Nasal Spray vs Omnaris in Seasonal Allergic Rhinitis
NCT02273817Phase 3Completed
- Sponsor
- Apotex Inc.
- Start
- Mar 2011
- Primary completion
- Aug 2011
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of ciclesonide in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Apotex Inc. Primary endpoint: Total Nasal Symptom Score at 14 days. Started Mar 2011; status: completed.
02
Drugs
ciclesonide
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT02273817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273817.